SYK vs TMO
Stryker Corporation vs Thermo Fisher Scientific — AI-powered side-by-side comparison
SYK
Stryker Corporation
59
Buy
VS
TMO
Thermo Fisher Scientific
69
Buy
| Metric | SYK | TMO |
|---|
| AI Score |
59
|
69
|
| Price |
$330.05
|
$632.13
|
| P/E Ratio |
33.98×
|
33.74×
|
| ROE |
14.5%
|
12.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
65.2%
|
40.4%
|
| Debt / Equity |
0.62×
|
0.81×
|
| Dividend Yield |
1.1%
|
0.3%
|
| RSI (14) |
44.6
|
77.6
|
| Beta |
0.771
|
0.847
|
| Expected Upside |
+13.1%
|
+2.5%
|
AI Committee View
Current Innellis committee reasoning for SYK versus TMO.
TMO leads by 10 points.
TMO scores 69/100 (Buy) versus SYK at 59/100 (Buy).
SYK Committee View
60% agreement
5 analysts
Positive signals support the current rating — eps growing 27.7% yoy. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- ROE of 16.4% shows genuine earnings power backing the valuation — Value
- EPS growing 27.7% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 35.2 is moderate-to-rich — Value
- Price-to-book of 6.0x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
TMO Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is sector concentration is already high (hhi 3068.56). The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 82 -- overbought on the larger timeframe too — Technical